vTv Therapeutics Inc. (VTVT): Shareholders' Equity
$64.44M
As of 2025-12-31
$78.63M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.44M | +428.2% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $12.20M | n/m | 2026-03-10, Balance as of period end |
| 2023-12-31 | -$24.68M | n/m | 2025-03-20, Balance as of period end |
| 2022-12-31 | -$10.74M | n/m | 2024-03-13, Balance as of period end |
| 2021-12-31 | -$9.74M | n/m | 2024-03-13, Balance as of period end |
| 2020-12-31 | -$80.10M | n/m | 2023-03-06, Balance as of period end |
| 2019-12-31 | -$49.02M | n/m | 2022-03-29, Balance as of period end |
| 2018-12-31 | -$82.85M | n/m | 2021-02-24, Balance as of period end |
| 2017-12-31 | -$151.05M | n/m | 2020-02-21, Balance as of period end |
| 2016-12-31 | -$90.94M | n/m | 2019-02-26, Balance as of period end |
| 2015-12-31 | -$77.97M | n/m | 2018-02-27, Balance as of period end |
| 2014-12-31 | -$498.81M | n/m | 2017-02-24, Balance as of period end |
| 2013-12-31 | -$303.73M | n/a | 2016-03-04, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $64.44M | +428.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare VTVT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗